Repatha® CV Outcomes Study: Adverse events and laboratory test results2,3

Repatha® Outcomes study adverse events Repatha® Outcomes study adverse events
  • In EBBINGHAUS, a substudy of 1,974 patients enrolled in the Outcomes trial, Repatha® was non-inferior to placebo on selected cognitive function domains as assessed with the use of neuropsychological function tests over a median follow-up of 19 months3

*Median LDL-C achieved at 48 weeks.3

The total number of patients was 8,337 in the Repatha® group and 8,339 in the placebo group, because patients with prevalent diabetes at the start of the trial were excluded.2